403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Oncolytics Biotech Inc
(MENAFN- Baystreet) 10:02 AM EST - Oncolytics Biotech Inc: Announced two abstracts across distinct tumor types were accepted for presentation at the American Association for Cancer Research Annual Meeting 2026, at the San Diego Convention Center from April 17-22, 2026. Pelareorep is an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways via double-stranded RNA signaling, driving interferon production, dendritic cell activation, and cytotoxic T-cell priming. Oncolytics Biotech Inc
shares N are trading off $0.01 at $0.95.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment